Abbott Laboratories Intrinsic Value Calculator – ABBOTT LABORATORIES Reports FY2022 Fourth Quarter Earnings Results on January 25 2023.
February 7, 2023
Earnings report
Abbott Laboratories Intrinsic Value Calculator – On January 25 2023, ABBOTT LABORATORIES ($NYSE:ABT) reported their earnings results for the fourth quarter of FY2022, ending on December 31 2022. ABBOTT LABORATORIES is a healthcare company that manufactures, distributes and markets a range of medical products, including diagnostics, pharmaceuticals and nutritional products. The company is listed on the New York Stock Exchange under the symbol ABT.
Total revenue for the quarter was reported as USD 1.0 billion, which represented a decline of 48.2% from the same period the previous year. Net income for the quarter was USD 10.1 billion, a decrease of 12.0% compared to the same time period in the previous year. Despite this, the company was able to increase its operating cash flow and reduce its outstanding debt during the period, providing it with a more secure financial position going forward.
Share Price
The stock opened at $110.0 and closed at $111.0, down 1.4% from its last closing price of $112.5. ABBOTT LABORATORIES reported strong performance in the fourth quarter in several key areas, including nutrition, diagnostics, medical devices and generic pharmaceuticals. Sales of generic pharmaceuticals were flat in the quarter compared to the prior year period. Overall, ABBOTT LABORATORIES reported strong results for the fourth quarter of FY2022 and is positioned for continued success in the coming quarters with its diversified product portfolio and strong cash flow and liquidity from operations. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbott Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 43.65k | 6.93k | 15.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbott Laboratories. More…
| Operations | Investing | Financing |
| 10.32k | -2.01k | -5.49k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 72.8k | 36.92k | 20.46 |
Key Ratios Snapshot
Some of the financial key ratios for Abbott Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.0% | 22.7% | 19.9% |
| FCF Margin | ROE | ROA |
| 19.6% | 15.2% | 7.5% |
Analysis – Abbott Laboratories Intrinsic Value Calculator
ABBOTT LABORATORIES is a healthcare company with a long history of providing high quality healthcare products and services. GoodWhale provides a comprehensive analysis of the company’s financials, and estimates the fair value of its share at around $127.3. The price of the share currently stands at $111.0, making it a 12.8% undervalued stock. ABBOTT LABORATORIES is well-established in the healthcare industry, as evidenced by its impressive financial performance. In addition to its impressive financial performance, ABBOTT LABORATORIES also has a strong balance sheet. This indicates that ABBOTT LABORATORIES is financially sound and able to manage any risks it may face in the future. Overall, ABBOTT LABORATORIES is an attractive stock for investors looking for a well-established healthcare company with strong financials and a low price-to-earnings ratio. It is currently undervalued by 12.8%, making it an attractive investment opportunity for those looking for long-term growth potential. More…
Peers
Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.
– OraSure Technologies Inc ($NASDAQ:OSUR)
OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.
OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.
– Quidel Corp ($NASDAQ:QDEL)
Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.
Summary
Investors looking to analyze the performance of ABBOTT LABORATORIES in the fourth quarter of FY2022 should take a close look at their revenue and net income. Total revenue for the quarter was USD 1.0 billion, which was a decline of 48.2% year over year. Reported net income was USD 10.1 billion, which was a decrease of 12.0%. The decline in revenue and net income is a concerning trend for investors, but the company has still reported strong growth over the past several years.
Analysts should also look at the company’s balance sheet and operations to get a better understanding of the company’s financial health. Investors should also consider the company’s competitive landscape, management team, and other risk factors before investing in ABBOTT LABORATORIES.
